{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:04:06Z","timestamp":1793934246819,"version":"4.8.0"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.cyto.2022.156015","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T13:24:56Z","timestamp":1661606696000},"page":"156015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["IL-33\/ST2 axis in autoimmune disease"],"prefix":"10.1016","volume":"158","author":[{"given":"Leila","family":"Shakerian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanieh","family":"Kolahdooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Garousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahideh","family":"Keyvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramiar","family":"Kamal Kheder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tola","family":"Abdulsattar Faraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmaeil","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9371-4170","authenticated-orcid":false,"given":"Seyed-Alireza","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2022.156015_b0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fimmu.2019.00015","article-title":"Cytokine Targeting by miRNAs in Autoimmune Diseases","volume":"10","author":"Salvi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0010","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/jhg.2015.94","article-title":"Genetics of autoimmune diseases: insights from population genetics","volume":"60","author":"Ramos","year":"2015","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.cyto.2022.156015_b0015","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-030-55035-6_6","article-title":"Immunoregulatory effects of tolerogenic probiotics in multiple sclerosis","author":"Atabati","year":"2021","journal-title":"Reviews on New Drug Targets in Age-Related Disorders."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-022-02782-7","article-title":"Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases","volume":"13","author":"Jasim","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.cyto.2022.156015_b0025","doi-asserted-by":"crossref","first-page":"587376","DOI":"10.1155\/2014\/587376","article-title":"Role of IL-33 and its receptor in T cell-mediated autoimmune diseases","volume":"2014","author":"Zhao","year":"2014","journal-title":"Biomed Res. Int."},{"key":"10.1016\/j.cyto.2022.156015_b0030","article-title":"SARS-CoV-2 triggering autoimmune diseases","volume":"155873","author":"Mobasheri","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2022.156015_b0035","article-title":"Detection of epidermal growth factor receptor T790M mutation by allele-specific loop mediated isothermal amplification","volume":"19","author":"Arjuna","year":"2020","journal-title":"Journal of Carcinogenesis."},{"issue":"11","key":"10.1016\/j.cyto.2022.156015_b0040","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/iub.2387","article-title":"The immunomodulatory effects of mesenchymal stromal cell-based therapy in human and animal models of systemic lupus erythematosus","volume":"72","author":"Radmanesh","year":"2020","journal-title":"IUBMB Life"},{"key":"10.1016\/j.cyto.2022.156015_b0045","unstructured":"Nori Mater H, Manaf Abd Al-Rhman R, R Ibraheem S, Shaker Mahmood M. Effects of Avena sativa and Glycyrrhiza glabra leaves extracts on immune responses in serum cytokine and liver enzyme levels in NIH mice. Archives of Razi Institute. 2022."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nri702","article-title":"Cytokines and autoimmunity","volume":"2","author":"O'Shea","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2022.156015_b0055","first-page":"1509","article-title":"Inhibitory effects of tolerogenic probiotics on migratory potential of lupus patient-derived DCs","volume":"24","author":"Esmaeili","year":"2021","journal-title":"Iranian J. Basic Medical Sciences."},{"key":"10.1016\/j.cyto.2022.156015_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155706","article-title":"Involvement of various chemokine\/chemokine receptor axes in trafficking and oriented locomotion of mesenchymal stem cells in multiple sclerosis patients","volume":"148","author":"Hassanshahi","year":"2021","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0065","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/s41598-017-00840-2","article-title":"Interleukin-33 regulates intestinal inflammation by modulating macrophages in inflammatory bowel disease","volume":"7","author":"Seo","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2022.156015_b0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coi.2014.09.004","article-title":"IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy","volume":"31","author":"Cayrol","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0075","doi-asserted-by":"crossref","unstructured":"Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J. immunology (Baltimore, Md : 1950). 2011;187(4):1609-16.","DOI":"10.4049\/jimmunol.1003080"},{"key":"10.1016\/j.cyto.2022.156015_b0080","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3389\/fimmu.2019.00522","article-title":"Pleiotropic Effects of IL-33 on CD4(+) T Cell Differentiation and Effector Functions","volume":"10","author":"Alvarez","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0085","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","article-title":"The ST2\/IL-33 Axis in Immune Cells during Inflammatory Diseases","volume":"8","author":"Griesenauer","year":"2017","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cyto.2022.156015_b0090","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1097\/MIB.0000000000000532","article-title":"IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function","volume":"21","author":"Waddell","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2017.08.004","article-title":"IL-1 Family Cytokines Use Distinct Molecular Mechanisms to Signal through Their Shared Co-receptor","volume":"47","author":"G\u00fcnther","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2022.156015_b0100","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.3389\/fimmu.2018.02506","article-title":"The Pro-tumorigenic IL-33 Involved in Antitumor Immunity: A Yin and Yang Cytokine","volume":"9","author":"Fourni\u00e9","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0105","article-title":"Role of the IL-33\/ST2L axis in colorectal cancer progression","author":"Akimoto","year":"2018","journal-title":"Cell. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2022.156015_b0110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nri2692","article-title":"Disease-associated functions of IL-33: the new kid in the IL-1 family","volume":"10","author":"Liew","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/bjc.2015.433","article-title":"An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer","volume":"114","author":"O'Donnell","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cyto.2022.156015_b0120","doi-asserted-by":"crossref","unstructured":"Mitsui A, Tada Y, Takahashi T, Shibata S, Kamata M, Miyagaki T, et al. Serum IL-33 levels are increased in patients with psoriasis2015.","DOI":"10.1111\/ced.12670"},{"key":"10.1016\/j.cyto.2022.156015_b0125","doi-asserted-by":"crossref","unstructured":"Hueber A, Alves-Filho JC, Asquith D, Michels C, Millar N, Reilly J, et al. IL\u201033 induces skin inflammation with mast cell and neutrophil activation2011. 2229-37 p.","DOI":"10.1002\/eji.201041360"},{"issue":"6","key":"10.1016\/j.cyto.2022.156015_b0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/cmi.2014.31","article-title":"Increased interleukin 33 in patients with neuro-Behcet's disease: correlation with MCP-1 and IP-10 chemokines","volume":"11","author":"Hamzaoui","year":"2014","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0135","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/imr.12552","article-title":"IL-33: biological properties, functions, and roles in airway disease","volume":"278","author":"Drake","year":"2017","journal-title":"Immunol. Rev."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0140","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.immuni.2005.10.004","article-title":"An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor","volume":"23","author":"Dinarello","year":"2005","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0145","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.cyto.2022.156015_b0150","doi-asserted-by":"crossref","unstructured":"Garth JM, Reeder KM, Godwin MS, Mackel JJ, Dunaway CW, Blackburn JP, et al. IL-33 Signaling Regulates Innate IL-17A and IL-22 Production via Suppression of Prostaglandin E2 during Lung Fungal Infection. J. immunology (Baltimore, Md : 1950). 2017;199(6):2140-8.","DOI":"10.4049\/jimmunol.1602186"},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-9255-8-22","article-title":"Role of IL-33 in inflammation and disease","volume":"8","author":"Miller","year":"2011","journal-title":"J. inflammation (London, England)."},{"issue":"3051","key":"10.1016\/j.cyto.2022.156015_b0160","article-title":"Interleukin-33 in Malignancies: Friends or Foes?","volume":"9","author":"Shen","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2022.156015_b0165","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrrheum.2011.53","article-title":"Interleukin-33 biology with potential insights into human diseases","volume":"7","author":"Palmer","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.02.021","article-title":"Potential Therapeutic Aspects of Alarmin Cytokine Interleukin 33 or Its Inhibitors in Various Diseases","volume":"38","author":"Arshad","year":"2016","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0175","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0002-9440(10)63631-0","article-title":"Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules","volume":"163","author":"Baekkevold","year":"2003","journal-title":"The American J. pathology."},{"key":"10.1016\/j.cyto.2022.156015_b0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","article-title":"The ST2\/IL-33 Axis in Immune Cells during Inflammatory Diseases","volume":"8","author":"Griesenauer","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210827","article-title":"IL-33 induction and signaling are controlled by glutaredoxin-1 in mouse macrophages","volume":"14","author":"Weinberg","year":"2019","journal-title":"PLoS ONE"},{"issue":"1\u20132","key":"10.1016\/j.cyto.2022.156015_b0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12026-012-8283-9","article-title":"IL-33\/ST2 axis in inflammation and immunopathology","volume":"52","author":"Milovanovic","year":"2012","journal-title":"Immunol. Res."},{"issue":"7","key":"10.1016\/j.cyto.2022.156015_b0195","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/ijc.28481","article-title":"Interleukin-33\/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells","volume":"134","author":"Jovanovic","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"2432","key":"10.1016\/j.cyto.2022.156015_b0200","article-title":"IL-33\/ST2 Axis in Organ Fibrosis","volume":"9","author":"Kotsiou","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.molonc.2015.06.004","article-title":"Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways","volume":"10","author":"Tong","year":"2016","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.cyto.2022.156015_b0210","first-page":"G821","article-title":"Nuclear expression of interleukin-33 in pancreatic stellate cells. American J. Physiology-Gastrointestinal and Liver","volume":"299","author":"Masamune","year":"2010","journal-title":"Physiology."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0215","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo","volume":"104","author":"Carriere","year":"2007","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.114.222505","article-title":"Targeting IL-33 in autoimmunity and inflammation","volume":"354","author":"Theoharides","year":"2015","journal-title":"The J. pharmacology and experimental therapeutics."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0225","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1042\/BST20170567","article-title":"New perspectives on IL-33 and IL-1 family cytokines as innate environmental sensors","volume":"46","author":"Scott","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.cyto.2022.156015_b0230","doi-asserted-by":"crossref","first-page":"608187","DOI":"10.1155\/2013\/608187","article-title":"The role of IL-33 in gut mucosal inflammation","volume":"2013","author":"Pastorelli","year":"2013","journal-title":"Mediators Inflamm."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0235","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1073\/pnas.1115884109","article-title":"IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G","volume":"109","author":"Lefrancais","year":"2012","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.cyto.2022.156015_b0240","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1684\/ecn.2012.0320","article-title":"Mechanisms of IL-33 processing and secretion: differences and similarities between IL-1 family members","volume":"23","author":"Lefrancais","year":"2012","journal-title":"Eur. Cytokine Netw."},{"issue":"43","key":"10.1016\/j.cyto.2022.156015_b0245","doi-asserted-by":"crossref","first-page":"15502","DOI":"10.1073\/pnas.1410700111","article-title":"Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells","volume":"111","author":"Lefrancais","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.cyto.2022.156015_b0250","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0255","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1128\/IAI.02908-14","article-title":"Crucial and Diverse Role of the Interleukin-33\/ST2 Axis in Infectious Diseases","volume":"83","author":"Rostan","year":"2015","journal-title":"Infect. Immun."},{"key":"10.1016\/j.cyto.2022.156015_b0260","article-title":"Immune-enhancing effect of bengkoang (Pachyrhizus erosus (L.) Urban) fiber fractions on mouse peritoneal macrophages, lymphocytes, and cytokines","author":"Baroroh","year":"20211284","journal-title":"J Nat Sci Biol Med."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0265","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092676","article-title":"The Role of IL-33\/ST2 Pathway in Tumorigenesis","volume":"19","author":"Larsen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0270","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/1756283X11410770","article-title":"Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation","volume":"4","author":"Pastorelli","year":"2011","journal-title":"Therap Adv Gastroenterol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0275","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41598-018-21589-2","article-title":"Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage","volume":"8","author":"Scott","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0280","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaci.2009.02.026","article-title":"IL-33-activated dendritic cells induce an atypical TH2-type response","volume":"123","author":"Rank","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"issue":"Suppl 2","key":"10.1016\/j.cyto.2022.156015_b0285","doi-asserted-by":"crossref","first-page":"i101","DOI":"10.1136\/annrheumdis-2011-200589","article-title":"IL-33: a Janus cytokine","volume":"71","author":"Liew","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.cyto.2022.156015_b0290","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nm.2156","article-title":"Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection","volume":"16","author":"Alves-Filho","year":"2010","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0295","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.cyto.2022.156015_b0300","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/imm.12988","article-title":"Interleukin-33 contributes to disease severity in Dengue virus infection in mice","volume":"155","author":"Marques","year":"2018","journal-title":"Immunology"},{"issue":"11","key":"10.1016\/j.cyto.2022.156015_b0305","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"37","key":"10.1016\/j.cyto.2022.156015_b0310","doi-asserted-by":"crossref","first-page":"14918","DOI":"10.1073\/pnas.1308651110","article-title":"Structural insights into the interaction of IL-33 with its receptors","volume":"110","author":"Liu","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"10.1016\/j.cyto.2022.156015_b0315","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0320","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13075-016-1042-x","article-title":"Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33","volume":"181","author":"Athari","year":"2016","journal-title":"Arthritis research & therapy."},{"issue":"10","key":"10.1016\/j.cyto.2022.156015_b0325","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.4049\/jimmunol.0904127","article-title":"ST2 negatively regulates TLR2 signaling, but is not required for bacterial lipoprotein-induced tolerance","volume":"184","author":"Liu","year":"2010","journal-title":"J. immunology (Baltimore, Md: 1950)"},{"issue":"11","key":"10.1016\/j.cyto.2022.156015_b0330","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.4049\/jimmunol.166.11.6633","article-title":"A novel pathway regulating lipopolysaccharide-induced shock by ST2\/T1 via inhibition of Toll-like receptor 4 expression","volume":"166","author":"Sweet","year":"2001","journal-title":"J. immunology (Baltimore, Md: 1950)"},{"issue":"2","key":"10.1016\/j.cyto.2022.156015_b0335","first-page":"179","article-title":"Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene Expression of IL-37 in Patients with Psoriasis Vulgaris","volume":"17","author":"Sehat","year":"2018","journal-title":"Iran J Allergy Asthma Immunol."},{"issue":"522","key":"10.1016\/j.cyto.2022.156015_b0340","article-title":"Pleiotropic Effects of IL-33 on CD4+ T Cell Differentiation and Effector Functions","volume":"10","author":"Alvarez","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0345","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-9255-8-22","article-title":"Role of IL-33 in inflammation and disease","volume":"8","author":"Miller","year":"2011","journal-title":"J. inflammation (London, England)"},{"issue":"4","key":"10.1016\/j.cyto.2022.156015_b0350","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.4049\/jimmunol.1002103","article-title":"IL-33 activates B1 cells and exacerbates contact sensitivity","volume":"186","author":"Komai-Koma","year":"2011","journal-title":"J. immunology (Baltimore, Md: 1950)"},{"issue":"18","key":"10.1016\/j.cyto.2022.156015_b0355","doi-asserted-by":"crossref","first-page":"4692","DOI":"10.1523\/JNEUROSCI.3233-16.2017","article-title":"ST2\/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury","volume":"37","author":"Yang","year":"2017","journal-title":"The J. Neuroscience."},{"key":"10.1016\/j.cyto.2022.156015_b0360","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.micpath.2018.04.050","article-title":"Study of serum bactericidal and splenic activity of Total-OMP-CagA combination from Brucella abortus and Helicobacter pylori in BALB\/c mouse model","volume":"121","author":"Abadi","year":"2018","journal-title":"Microb. Pathog."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/imm.12174","article-title":"Emerging role of interleukin-33 in autoimmune diseases","volume":"141","author":"Pei","year":"2014","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0370","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"Filippi","year":"2018","journal-title":"Multiple sclerosis. Nat Rev Dis Primers."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0375","doi-asserted-by":"crossref","first-page":"40","DOI":"10.5001\/omj.2016.08","article-title":"Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis","volume":"31","author":"Jafarzadeh","year":"2016","journal-title":"Oman Med J."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0380","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/bmc-2016-0026","article-title":"Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis","volume":"8","author":"Alsahebfosoul","year":"2017","journal-title":"Biomol Concepts."},{"issue":"4","key":"10.1016\/j.cyto.2022.156015_b0385","first-page":"329","article-title":"Correlation of Serum Levels of IL-33, IL-37, Soluble Form of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and Circulatory Frequency of VEGFR2-expressing Cells with Multiple Sclerosis Severity","volume":"16","author":"Kouchaki","year":"2017","journal-title":"Iran J Allergy Asthma Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0390","article-title":"Neuroinflammation Induces Neurodegeneration","volume":"1","author":"Kempuraj","year":"2016","journal-title":"J Neurol Neurosurg Spine."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0395","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40478-016-0344-1","article-title":"Role of IL-33 and ST2 signalling pathway in multiple sclerosis: expression by oligodendrocytes and inhibition of myelination in central nervous system","volume":"4","author":"Allan","year":"2016","journal-title":"Acta Neuropathol Commun."},{"issue":"6","key":"10.1016\/j.cyto.2022.156015_b0400","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1161\/STROKEAHA.120.032444","article-title":"IL33 (Interleukin 33)\/ST2 (Interleukin 1 Receptor-Like 1) axis drives protective microglial responses and promotes white matter integrity after stroke","volume":"52","author":"Xie","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.cyto.2022.156015_b0405","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.molimm.2018.08.026","article-title":"Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells","volume":"101","author":"Xiao","year":"2018","journal-title":"Mol. Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2022.156015_b0410","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/eji.201141947","article-title":"IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages","volume":"42","author":"Jiang","year":"2012","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2022.156015_b0415","first-page":"703","article-title":"Helminth Products Protect against Autoimmunity via Innate Type 2 Cytokines IL-5 and IL-33","volume":"196","author":"Finlay","year":"2016","journal-title":"Which Promote Eosinophilia. J Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2022.156015_b0420","doi-asserted-by":"crossref","first-page":"E1520","DOI":"10.1073\/pnas.1710401115","article-title":"Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility","volume":"115","author":"Russi","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0425","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045225","article-title":"Deletion of IL-33R (ST2) abrogates resistance to EAE in BALB\/C mice by enhancing polarization of APC to inflammatory phenotype","volume":"7","author":"Milovanovic","year":"2012","journal-title":"PLoS ONE"},{"issue":"1\u20132","key":"10.1016\/j.cyto.2022.156015_b0430","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jneuroim.2012.03.016","article-title":"IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL\/6 mice","volume":"247","author":"Li","year":"2012","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.cyto.2022.156015_b0435","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10238-010-0115-4","article-title":"Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population","volume":"11","author":"Yang","year":"2011","journal-title":"Clin Exp Med."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0440","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/mmr.2015.4516","article-title":"IL33 and kidney disease (Review)","volume":"13","author":"Yang","year":"2016","journal-title":"Mol. Med. Rep."},{"issue":"7","key":"10.1016\/j.cyto.2022.156015_b0445","first-page":"1295","article-title":"The IL33\/ST2 axis in Sjogren syndrome in relation to disease activity","volume":"20","author":"Margiotta","year":"2016","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.cyto.2022.156015_b0450","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/924363","article-title":"The role of IL-33 in rheumatic diseases","volume":"2013","author":"Duan","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0455","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/eg3a2k","article-title":"Soluble ST2 is increased in systemic lupus erythematous and is a potential marker of lupus nephritis","author":"Moreau","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"issue":"21","key":"10.1016\/j.cyto.2022.156015_b0460","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.147671","article-title":"NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN-\u03b1 production in patients with SLE","volume":"6","author":"Georgakis","year":"2021","journal-title":"JCI insight."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0465","doi-asserted-by":"crossref","DOI":"10.21037\/atm-20-4729","article-title":"Interleukin (IL)-1 family cytokines could differentiate primary immune thrombocytopenia from systemic lupus erythematosus-associated thrombocytopenia","volume":"9","author":"Zhan","year":"2021","journal-title":"Annals of Translational Medicine."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1525-z","article-title":"IL-1 family cytokines and soluble receptors in systemic lupus erythematosus","volume":"20","author":"Italiani","year":"2018","journal-title":"Arthritis research & therapy."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0475","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10753-013-9802-0","article-title":"IL-33 neutralization suppresses lupus disease in lupus-prone mice","volume":"37","author":"Li","year":"2014","journal-title":"Inflammation."},{"key":"10.1016\/j.cyto.2022.156015_b0480","article-title":"Interleukin-33 contributes toward loss of tolerance by promoting B-cell-activating factor of the tumor-necrosis-factor family (BAFF)-dependent autoantibody production","volume":"2871","author":"Rose","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0485","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112448","article-title":"Early treatment of interleukin-33 can attenuate lupus development in young NZB\/W F1 mice","author":"Mohd Jaya","year":"20209112448","journal-title":"Cells."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0490","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.4049\/jimmunol.1100519","article-title":"IL-33 expands suppressive CD11b+ Gr-1int and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival","volume":"187","author":"Turnquist","year":"2011","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0495","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.humimm.2013.06.029","article-title":"IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy","volume":"74","author":"Xu","year":"2013","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.cyto.2022.156015_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2019.114702","article-title":"Efficacy and safety of Ramucirumab and methotrexate co-therapy in rheumatoid arthritis experimental model: Involvement of angiogenic and immunomodulatory signaling","volume":"380","author":"Abdel-Maged","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.cyto.2022.156015_b0505","doi-asserted-by":"crossref","first-page":"R105","DOI":"10.1186\/ar4554","article-title":"Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis","volume":"16","author":"Li","year":"2014","journal-title":"Arthritis Res Ther."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0510","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/ard.2009.122655","article-title":"IL-33 induces neutrophil migration in rheumatoid arthritis and is a target of anti-TNF therapy","volume":"69","author":"Verri","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0515","first-page":"1799","article-title":"Study the Ability of Salmonella typhimiurm to Induce Cytokine TNF\u03b1 in Mice Treated with Olive Leaves Extract and Ciprofloxacin","volume":"77","author":"Al Mnshad","year":"2022","journal-title":"Arch. Razi Inst."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0520","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3346\/jkms.2011.26.9.1132","article-title":"Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis","volume":"26","author":"Hong","year":"2011","journal-title":"J. Korean Med. Sci."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0525","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens8030126","article-title":"Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome","volume":"8","author":"Khan","year":"2019","journal-title":"Pathogens."},{"issue":"12","key":"10.1016\/j.cyto.2022.156015_b0530","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1172\/JCI88625","article-title":"IL-33 regulates the IgA-microbiota axis to restrain IL-1alpha-dependent colitis and tumorigenesis","volume":"126","author":"Malik","year":"2016","journal-title":"J Clin Invest."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0535","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ecco-jcc\/jjx139","article-title":"Transcriptomic Landscape of Treatment-Naive Ulcerative Colitis","volume":"12","author":"Taman","year":"2018","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.cyto.2022.156015_b0540","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cyto.2018.08.009","article-title":"Interleukin 33 regulates gene expression in intestinal epithelial cells independently of its nuclear localization","volume":"111","author":"He","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2022.156015_b0545","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3389\/fimmu.2019.01091","article-title":"IL-33 and IL-18 in Inflammatory Bowel Disease Etiology and Microbial Interactions","volume":"10","author":"Williams","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0550","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1038\/s41598-017-10465-0","article-title":"A functional IL1RL1 variant regulates corticosteroid-induced sST2 expression in ulcerative colitis","volume":"7","author":"Diaz-Jimenez","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0555","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/imm.12111","article-title":"Interleukin-33 exacerbates acute colitis via interleukin-4 in mice","volume":"140","author":"Pushparaj","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.cyto.2022.156015_b0560","doi-asserted-by":"crossref","first-page":"35403","DOI":"10.1038\/srep35403","article-title":"Loss of interleukin 33 expression in colonic crypts - a potential marker for disease remission in ulcerative colitis","volume":"6","author":"Gundersen","year":"2016","journal-title":"Sci. Rep."},{"issue":"40","key":"10.1016\/j.cyto.2022.156015_b0565","doi-asserted-by":"crossref","first-page":"E9362","DOI":"10.1073\/pnas.1803613115","article-title":"IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair","volume":"115","author":"Lopetuso","year":"2018","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.cyto.2022.156015_b0570","doi-asserted-by":"crossref","first-page":"509764","DOI":"10.1155\/2013\/509764","article-title":"Autoimmune thyroid disorders","volume":"2013","author":"Iddah","year":"2013","journal-title":"ISRN Endocrinol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0575","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF02893034","article-title":"Autoimmune thyroid disorders-An update","volume":"20","author":"Swain","year":"2005","journal-title":"Indian J. Clin. Biochem."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0580","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/jcp.27180","article-title":"The pathogenesis of thyroid autoimmune diseases: New T lymphocytes - Cytokines circuits beyond the Th1-Th2 paradigm","volume":"234","author":"Li","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.cyto.2022.156015_b0585","first-page":"4024","article-title":"Different levels of circulating Th22 cell and its related molecules in Graves' disease and Hashimoto's thyroiditis","volume":"7","author":"Song","year":"2014","journal-title":"Int J Clin Exp Pathol."},{"key":"10.1016\/j.cyto.2022.156015_b0590","doi-asserted-by":"crossref","unstructured":"Celik H, Abusoglu S, F Burnik S, Sezer S, Serdar M, Ercan M, et al. Increased serum interleukin-33 levels in patients with Graves' disease2013. 57-64 p.","DOI":"10.4149\/endo_2013_02_57"},{"key":"10.1016\/j.cyto.2022.156015_b0595","series-title":"Endocrine, Metabolic & Immune Disorders Drug Targets","article-title":"Dysregulated Interleukin -33\/ST2 Pathway Perpetuate Chronic Inflammation in Hashimoto's Thyroiditis","author":"Wang","year":"2019"},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0600","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/iji.12240","article-title":"Polymorphisms of ST2-IL18R1-IL18RAP gene cluster: a new risk for autoimmune thyroid diseases","volume":"43","author":"Wang","year":"2016","journal-title":"Int. J. Immunogenet."},{"issue":"2","key":"10.1016\/j.cyto.2022.156015_b0605","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3899\/jrheum.140234","article-title":"The Interleukin 33\/ST2 axis in patients with primary Sjogren syndrome: expression in serum and salivary glands, and the clinical association","volume":"42","author":"Jung","year":"2015","journal-title":"The J. rheumatology."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0610","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cyto.2013.07.006","article-title":"Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome","volume":"64","author":"Zhao","year":"2013","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.cyto.2022.156015_b0615","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00296-018-4063-8","article-title":"Smoking, disease characteristics and serum cytokine levels in patients with primary Sjogren's syndrome","volume":"38","author":"Olsson","year":"2018","journal-title":"Rheumatol. Int."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0620","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","article-title":"Advances in understanding the pathogenesis of primary Sjogren's syndrome","volume":"9","author":"Nocturne","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.cyto.2022.156015_b0625","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/annrheumdis-2012-203187","article-title":"Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome","volume":"73","author":"Awada","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102756","article-title":"Pathophysiologic role of Interleukin-33\/ST2 in Sj\u00f6gren's syndrome","volume":"20","author":"Soyfoo","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0635","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/ijo.IJO_405_17","article-title":"Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease","volume":"66","author":"Luo","year":"2018","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.cyto.2022.156015_b0640","doi-asserted-by":"crossref","first-page":"7692024","DOI":"10.1155\/2016\/7692024","article-title":"T Helper Cell Subsets in Clinical Manifestations of Psoriasis","volume":"2016","author":"Diani","year":"2016","journal-title":"J Immunol Res."},{"issue":"11","key":"10.1016\/j.cyto.2022.156015_b0645","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/jid.2012.185","article-title":"Regulation of IL-33 expression by IFN-gamma and tumor necrosis factor-alpha in normal human epidermal keratinocytes","volume":"132","author":"Meephansan","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0650","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1073\/pnas.1000803107","article-title":"IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin","volume":"107","author":"Theoharides","year":"2010","journal-title":"PNAS"},{"issue":"8","key":"10.1016\/j.cyto.2022.156015_b0655","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/eji.201041360","article-title":"IL-33 induces skin inflammation with mast cell and neutrophil activation","volume":"41","author":"Hueber","year":"2011","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2022.156015_b0660","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ced.12670","article-title":"Serum IL-33 levels are increased in patients with psoriasis","volume":"41","author":"Mitsui","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.07.027","article-title":"An autocrine circuit of IL-33 in keratinocytes is involved in the progression of psoriasis","volume":"141","author":"Zeng","year":"2021","journal-title":"J, Invest. Dermatol."},{"key":"10.1016\/j.cyto.2022.156015_b0670","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cyto.2019.02.019","article-title":"IL-33 contributes to disease severity in psoriasis-like models of mouse","volume":"119","author":"Duan","year":"2019","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0675","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000471798","article-title":"New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions","volume":"233","author":"Li","year":"2017","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.cyto.2022.156015_b0680","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/exd.12027","article-title":"IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation","volume":"21","author":"Balato","year":"2012","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0685","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jbspin.2011.02.011","article-title":"Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis","volume":"79","author":"Talabot-Ayer","year":"2012","journal-title":"Joint Bone Spine."},{"issue":"23","key":"10.1016\/j.cyto.2022.156015_b0690","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.3390\/ijms20235856","article-title":"IL-33\/IL-31 axis in immune-mediated and allergic diseases","volume":"20","author":"Murdaca","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"20","key":"10.1016\/j.cyto.2022.156015_b0695","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.3390\/ijms20205226","article-title":"The ST2\/interleukin-33 axis in hematologic malignancies: the IL-33 paradox","volume":"20","author":"Allegra","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0700","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/medicina56030138","article-title":"Alarmins in osteoporosis, RAGE, IL-1, and IL-33 pathways: a literature review","volume":"56","author":"De Martinis","year":"2020","journal-title":"Medicina."},{"key":"10.1016\/j.cyto.2022.156015_b0705","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7158014","article-title":"Possible roles of IL-33 in the innate-adaptive immune crosstalk of psoriasis pathogenesis","volume":"2019","author":"Cannav\u00f2","year":"2019","journal-title":"Mediators Inflamm."},{"issue":"3","key":"10.1016\/j.cyto.2022.156015_b0710","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00403-014-1447-9","article-title":"IL-33 is regulated by TNF-alpha in normal and psoriatic skin","volume":"306","author":"Balato","year":"2014","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cyto.2022.156015_b0715","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.3389\/fimmu.2018.02646","article-title":"IL-33 Prevents MLD-STZ Induction of Diabetes and Attenuate Insulitis in Prediabetic NOD Mice","volume":"9","author":"Pavlovic","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2022.156015_b0720","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4239\/wjd.v6.i6.828","article-title":"Enterovirus and type 1 diabetes: What is the matter?","volume":"6","author":"Bergamin","year":"2015","journal-title":"World J Diabetes."},{"key":"10.1016\/j.cyto.2022.156015_b0725","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.intimp.2019.02.018","article-title":"Interleukin-33 prevents the development of autoimmune diabetes in NOD mice","volume":"70","author":"Lu","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0730","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1084\/jem.20100209","article-title":"IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells","volume":"207","author":"Grinberg-Bleyer","year":"2010","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.cyto.2022.156015_b0735","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial","volume":"1","author":"Hartemann","year":"2013","journal-title":"The lancet Diabetes & endocrinology."},{"issue":"9","key":"10.1016\/j.cyto.2022.156015_b0740","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127- regulatory T cells preserves beta-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.cyto.2022.156015_b0745","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/imm.12065","article-title":"Transient depletion of CD4+ CD25+ regulatory T cells results in multiple autoimmune diseases in wild-type and B-cell-deficient NOD mice","volume":"139","author":"Ellis","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.cyto.2022.156015_b0750","doi-asserted-by":"crossref","first-page":"9429760","DOI":"10.1155\/2016\/9429760","article-title":"IL-33 Effect on Quantitative Changes of CD4(+)CD25(high)FOXP3(+) Regulatory T Cells in Children with Type 1 Diabetes","volume":"2016","author":"Ryba-Stanislawowska","year":"2016","journal-title":"Mediators Inflamm."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0755","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molimm.2008.12.023","article-title":"Regulatory T cells and ST2 signaling control diabetes induction with multiple low doses of streptozotocin","volume":"47","author":"Zdravkovic","year":"2009","journal-title":"Mol. Immunol."},{"issue":"665","key":"10.1016\/j.cyto.2022.156015_b0760","article-title":"Immunopathogenesis of Behcet's Disease","volume":"10","author":"Tong","year":"2019","journal-title":"Front. Immunol."},{"issue":"3 Suppl 77","key":"10.1016\/j.cyto.2022.156015_b0765","first-page":"6","article-title":"Serum IL-33 levels and skin mRNA expression in Behcet's disease","volume":"31","author":"Hamzaoui","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"issue":"8","key":"10.1016\/j.cyto.2022.156015_b0770","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3346\/jkms.2013.28.8.1145","article-title":"Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet's disease","volume":"28","author":"Kim","year":"2013","journal-title":"J. Korean Med. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0775","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4291\/wjgp.v5.i1.11","article-title":"Pathophysiology of autoimmune pancreatitis","volume":"5","author":"Pezzilli","year":"2014","journal-title":"World J. gastrointestinal pathophysiology."},{"issue":"11","key":"10.1016\/j.cyto.2022.156015_b0780","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.it.2018.09.005","article-title":"Mechanistic insights into autoimmune pancreatitis and IgG4-related disease","volume":"39","author":"Watanabe","year":"2018","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2022.156015_b0785","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/mi.2015.144","article-title":"Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis","volume":"9","author":"Watanabe","year":"2016","journal-title":"Mucosal Immunol."},{"issue":"10","key":"10.1016\/j.cyto.2022.156015_b0790","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.4049\/jimmunol.1700060","article-title":"Chronic fibro-inflammatory responses in autoimmune pancreatitis depend on IFN-\u03b1 and IL-33 produced by plasmacytoid dendritic cells","volume":"198","author":"Watanabe","year":"2017","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2022.156015_b0795","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.4049\/jimmunol.1500971","article-title":"Plasmacytoid dendritic cell activation and IFN-\u03b1 production are prominent features of murine autoimmune pancreatitis and human IgG4-related autoimmune pancreatitis","volume":"195","author":"Arai","year":"2015","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0800","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/art.41052","article-title":"Activated M2 macrophages contribute to the pathogenesis of IgG4-related disease via Toll-like receptor 7\/interleukin-33 signaling","volume":"72","author":"Ishiguro","year":"2020","journal-title":"Arthritis & Rheumatology."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42413","article-title":"Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease","volume":"7","author":"Furukawa","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.cyto.2022.156015_b0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-71848-4","article-title":"Identification of serum IFN-\u03b1 and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease","volume":"10","author":"Minaga","year":"2020","journal-title":"Sci. Rep."},{"issue":"390","key":"10.1016\/j.cyto.2022.156015_b0815","first-page":"2","article-title":"Serum Level of Interleukin 33 and its Relation with Disease Activity and Clinical Presentation in Systemic Lupus Erythematosus","volume":"8","author":"Toama","year":"2017","journal-title":"J Clin Exp Dermatol Res."},{"issue":"316","key":"10.1016\/j.cyto.2022.156015_b0820","first-page":"1","article-title":"A Comparative Review of Toll-Like Receptor 4 Expression and Functionality in Different Animal Species","volume":"5","author":"Vaure","year":"2014","journal-title":"Front. Immunol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622002241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466622002241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:47:16Z","timestamp":1760910436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466622002241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":164,"alternative-id":["S1043466622002241"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2022.156015","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-33\/ST2 axis in autoimmune disease","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2022.156015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156015"}}